Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 555,199 shares changed hands during trading, an increase of 65% from the previous session’s volume of 336,546 shares.The stock last traded at $8.94 and had previously closed at $8.9875.
Coloplast A/S Price Performance
The company has a quick ratio of 1.00, a current ratio of 1.61 and a debt-to-equity ratio of 1.20. The firm’s 50-day moving average is $8.89 and its 200-day moving average is $9.19. The company has a market cap of $20.15 billion, a PE ratio of 37.25, a PEG ratio of 0.84 and a beta of 0.26.
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). Coloplast A/S had a return on equity of 24.99% and a net margin of 13.01%.The firm had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. On average, equities analysts anticipate that Coloplast A/S Sponsored ADR will post 0.31 EPS for the current year.
About Coloplast A/S
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Recommended Stories
- Five stocks we like better than Coloplast A/S
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- This stock gets a 94 out of 100
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
